CLINICAL TRIALS PROFILE FOR FIBRICOR

All Clinical Trials for FIBRICOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00961116 ↗	Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)	Completed	Mutual Pharmaceutical Company, Inc.	Phase 1	2007-10-01	This study will evaluate the bioequivalence of 105 mg fenofibric acid tablets relative to 145 mg fenofibrate tablets in healthy volunteers under fasting conditions. A secondary objective is to characterize the pharmacokinetic profile of fenofibric acid when administered as a single 105 mg dose to healthy volunteers in a fasted state. Safety and tolerability of this regimen will also be evaluated.
NCT01472380 ↗	A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz	Completed	Mutual Pharmaceutical Company, Inc.	Phase 1	2011-11-01	Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of single-dose efavirenz in healthy adult subjects.

Clinical Trial Conditions for FIBRICOR

Condition Name

Condition Name for FIBRICOR
Intervention	Trials
Healthy	2

Condition MeSH

Condition MeSH for FIBRICOR
Intervention	Trials

Clinical Trial Locations for FIBRICOR

Trials by Country

Trials by Country for FIBRICOR
Location	Trials
United States	2

Trials by US State

Trials by US State for FIBRICOR
Location	Trials
West Virginia	1
North Dakota	1

Clinical Trial Progress for FIBRICOR

Clinical Trial Phase

Clinical Trial Phase for FIBRICOR
Clinical Trial Phase	Trials
Phase 1	2

Clinical Trial Status

Clinical Trial Status for FIBRICOR
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for FIBRICOR

Sponsor Name

Sponsor Name for FIBRICOR
Sponsor	Trials
Mutual Pharmaceutical Company, Inc.	2

Sponsor Type

Sponsor Type for FIBRICOR
Sponsor	Trials
Industry	2